Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals

Bioorganic and Medicinal Chemistry

Volumn 24, Issue 24, 2016, Pages 6446-6451

  Sinha, Michael S ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibiotics; FDA; Market exclusivity

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG CONTROL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; PATENT; PREVALENCE; RISK BENEFIT ANALYSIS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; SYNTHESIS; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85002338988     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2016.08.033     Document Type: Article

References (51)

1. 1 Fauci, A.S., Clin. Infect. Dis., 32, 2001, 675.
2. 2 Institute of Medicine Committee on Emerging Microbial Threats to Health, Emerging Infections: Microbial Threats to Health in the United States. 1992 Washington, DC, http://www.nap.edu/catalog/2008/emerging-infections-microbial-threats-to-health-in-the-united-states.
3. 3 Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2013. 2013 Washington, DC, http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
4. 4 World Health Organization, Antimicrobial Resistance: Global Report on Surveillance. 2014 Geneva, http://www.who.int/drugresistance/documents/surveillancereport/en/.
5. 5 Coates, A., Hu, Y., Bax, R., Page, C., Nat. Rev. Drug Disc., 1, 2002, 895.
6. 6 Projan, S.J., Curr. Opin. Microbiol., 6, 2003, 427.
7. 7 Sertkaya, A., Eyraud, J., Birkenbach, A., et al. Analytical Framework for Examining the Value of Antibacterial Products. 2014 https://aspe.hhs.gov/sites/default/files/pdf/76891/rpt_antibacterials.pdf.
8. 8 Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. 2016 http://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.
9. 9 Renwick, M.J., Brogan, D.M., Mossialos, E., J. Antibiot. (Tokyo), 69, 2016, 73.
10. 10 Morel, C.M., Mossialos, E., BMJ, 340, 2010, c2115.
11. 11 Spellberg, B., Blaser, M., Guidos, R.J., et al. Clin. Infect. Dis., 52, 2011, S397.
12. 12 Alqahtani, S., Seoane-Vazquez, E., Rodriguez-Monguio, R., Eguale, T., Pharmacoepidemiol. Drug Saf., 24, 2015, 709.
13. 13 Kaitin, K.I., DiMasi, J.A., Clin. Pharmacol. Ther., 89, 2011, 183.
14. 14 Office of the Assistant Secretary for Planning and Evaluation. Examination of Clinical Trial Costs and Barriers for Drug Development, 2014. https://aspe.hhs.gov/report/examination-clinical-trial-costs-and-barriers-drug-development.
15. 15 Hwang, T.J., Kesselheim, A.S., Am. J. Law Med., 42, 2016, 429.
16. 16 Hwang, T.J., Carpenter, D., Kesselheim, A.S., Science, 344, 2014, 967.
17. 17 Food & Drug Administration, Guidance for Industry (Draft): Non-Inferiority Clinical Trials. 2010 http://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf.
18. 18 Deak, D., Outterson, K., Powers, J.H., Kesselheim, A.S., Ann. Intern. Med., 2016 [Epub ahead of print].
19. 19 Nambiar, S., Laessig, K., Toerner, J., Farley, J., Cox, E., Clin. Pharmacol. Ther., 96, 2014, 147.
20. 20 Everson-Stewart, S., Emerson, S.S., Stat. Med., 29, 2010, 2769.
21. 21 Infectious Diseases Society of America. Drug Companies, Health Groups Back IDSA Proposal, 2012. http://www.idsociety.org/2012_LPAD_Proposal_Backing/.
22. 22 Rex, J.H., Eisenstein, B.I., Alder, J., et al. Lancet Infect. Dis., 13, 2013, 269.
23. 23 Parker, I., New Yorker, 2013.
24. 24 Spellberg, B., Crit. Care, 18, 2014, 228.
25. 25 Avorn, J., Kesselheim, A.S., N. Eng. J. Med., 372, 2015, 2473.
26. 26 Hoque, R., Chesson, A.L. Jr., J. Clin. Sleep Med., 5, 2009, 471.
27. 27 United States v. Caronia, 703 F.3d 149, (2d Cir. 2012).
28. 28 Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2015. H.R. 512. Introduced in the U.S. House of Representatives January 22, 2015.
29. 29 Hernandez, J., Machacz, S.F., Robinson, J.C., Health Aff. (Millwood), 34, 2015, 261.
30. 30 Young, K. Medicare Rejects Most Bids for New Technology Add-On Payment, 2015. http://www.commonwealthfund.org/publications/newsletters/washington-health-policy-in-review/2015/aug/aug-10-2015/medicare-rejects-most-bids-for-new-technology-addon-payment.
31. 31 Fox, G.J., Menzies, D., Infect. Dis. Ther., 2, 2013, 123.
32. 32 Field, S.K., Ther. Adv. Chronic Dis., 6, 2015, 170.
33. 33 Talbot, G.H., Powers, J.H., Hoffmann, S.C., Clin. Infect. Dis., 62, 2016, 603.
34. 34 Floyd, J.S., Psaty, B.M., JAMA Intern. Med., 174, 2014, 1436.
35. 35 Sarpatwari, A., Kesselheim, A.S., Clin. Pharmacol. Ther., 98, 2015, 575.
36. 36 Ridley, D.B., Grabowski, H.G., Moe, J.L., Health Aff. (Millwood), 25, 2006, 313.
37. 37 Ridley, D.B., Regnier, S.A., Health Aff. (Millwood), 35, 2016, 776.
38. 38 Silverman, E. FDA Wants to Nix Voucher System for Rare Pediatric Disease Drugs, 2016. https://www.statnews.com/pharmalot/2016/03/03/fda-pediatric-disease-gao/.
39. 39 Food & Drug Administration, A Brief Overview of Risk Evaluation & Mitigation Strategies (REMS). 2015 http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf.
40. 40 Wang, B., Liu, J., Kesselheim, A.S., JAMA Intern. Med., 175, 2015, 635.
41. 41 United States Government Accountability Office, New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. 2006 http://www.gao.gov/new.items/d0749.pdf.
42. 42 Kades, E., Northwestern Univ. Law Rev., 99, 2005, 611.
43. 43 Outterson, K., Univ. Pitt. Law Rev., 67, 2005, 67 (see footnote 206).
44. 44 Tillotson, J., Tillotson, G.S., Clin. Infect. Dis., 61, 2015, S678.
45. 45 Federal Register. Establishing A List of Qualifying Pathogens under the Food and Drug Administration Safety and Innovation Act. 2014, 79, 32464–32481.
46. 46 Updated List of QIDP Antibiotics. 2015 http://allphasepharma.com/dir/2015/12/23/2205/qidp-antibiotics-2015-year-end-update/.
47. 47 Spellberg, B., Sharma, P., Rex, J.H., Nat. Rev. Drug Disc., 11, 2012, 168.
48. 48 Outterson, K., Samora, J.B., Keller-Cuda, K., Lancet Infect. Dis., 7, 2007, 559.
49. 49 U.S. House of Representatives, Energy and Commerce Committee, Subcommittee on Health, 21st Century Cures Act, Discussion Document. 2015 https://energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/114/Analysis/Cures/20150127-Cures-Discussion-Document.pdf.
50. 50 Outterson, K., McDonnell, A., Health Aff. (Millwood), 35, 2016, 784.
51. 51 Thomas, A. Examining Ways to Combat Antibiotic Resistance and Foster New Drug Development, Subcommittee on Health, Committee on Energy and Commerce, 2014.